Articles

Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin

Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany; NCT Trial Center, National Center of Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg
Istituto di Ematologia "Seràgnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università degli Studi, Bologna
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
Haematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan
Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig
Massachusetts General Hospital, Boston, MA
Department of Hematology and Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg
Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany; Praxis for Hematology and Oncology Koblenz, Koblenz
Department of Hematology and Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg
Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
NCT Trial Center, National Center of Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli” Bologna
Haematologica Early view Feb 10, 2022 https://doi.org/10.3324/haematol.2021.280433